Literature DB >> 7083500

Arterial oxygenation and arterial oxygen transport in chronic myocardial failure at rest, during exercise and after hydralazine treatment.

S A Rubin, H V Brown, H J Swan.   

Abstract

Arterial oxygen transport (cardiac output x arterial oxygen content) may be decreased in heart failure. We studied the determinants of arterial oxygen transport in 15 patients with chronic, severe myocardial failure at rest and during cycle ergometry. During control therapy at rest, arterial oxygen tension was normal (81 +/- 8 mm Hg, mean +/- SD) and increased slightly during exercise (90 +/- 14 mm Hg). During hydralazine therapy at rest, arterial oxygen tension was slightly higher (87 +/- 9 mm Hg) and also increased during exercise (92 +/- 15 mm Hg). Hydralazine did not increase arterial oxygen tension (0.10 greater than p greater than 0.05), but exercise did (p less than 0.02). Arterial oxygen saturation and content were normal and did not change under any condition or treatment. During control therapy at rest, arterial oxygen transport was low (313 +/- 74 ml/min . m2) and remained abnormally low during exercise (434 +/- 124 ml/min . m2). During hydralazine therapy, arterial oxygen transport was higher at rest (457 +/- 100 ml/min . m2) and during exercise (577 +/- 131 ml/min . m2). Hydralazine increased arterial oxygen transport (p less than 0.01) because it increased stroke volume at rest and during exercise, but it did not change arterial oxygenation. Arterial oxygenation is normal in chronic heart failure patients at rest and during exercise. Hydralazine increases cardiac output and arterial oxygen transport without changing arterial oxygenation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7083500     DOI: 10.1161/01.cir.66.1.143

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Factors which alter the relationship between ventilation and carbon dioxide production during exercise in normal subjects.

Authors:  A L Clark; M Volterrani; M Piepoli; A J Coats
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

2.  Relative contribution of resting haemodynamic profile and lung function to exercise tolerance in male patients with chronic heart failure.

Authors:  P Faggiano; A D'Aloia; A Gualeni; A Giordano
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

3.  A possible role for systemic hypoxia in the reactive component of pulmonary hypertension in heart failure.

Authors:  Bryan J Taylor; Cesar R Mojica; Thomas P Olson; Paul R Woods; Robert P Frantz; Bruce D Johnson
Journal:  J Card Fail       Date:  2013-01       Impact factor: 5.712

Review 4.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

Review 5.  Exercise for patients with congestive heart failure.

Authors:  R J Shephard
Journal:  Sports Med       Date:  1997-02       Impact factor: 11.136

6.  The increased ventilatory response to exercise in chronic heart failure: relation to pulmonary pathology.

Authors:  A L Clark; M Volterrani; J W Swan; A J Coats
Journal:  Heart       Date:  1997-02       Impact factor: 5.994

7.  Mechanism of the increased ventilatory response to exercise in patients with chronic heart failure.

Authors:  N P Buller; P A Poole-Wilson
Journal:  Br Heart J       Date:  1990-05

8.  Usefulness of arterial blood gas estimations during exercise in patients with chronic heart failure.

Authors:  A L Clark; A J Coats
Journal:  Br Heart J       Date:  1994-06

9.  Perfusion/ventilation mismatch during exercise in chronic heart failure: an investigation of circulatory determinants.

Authors:  A P Banning; N P Lewis; D B Northridge; J S Elborn; A H Hendersen
Journal:  Br Heart J       Date:  1995-07

10.  Factors determining symptoms in heart failure: comparison of fast and slow exercise tests.

Authors:  D P Lipkin; R Canepa-Anson; M R Stephens; P A Poole-Wilson
Journal:  Br Heart J       Date:  1986-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.